Diquafosol

Diquafosol
Names
IUPAC name
O1,O7-Di(5′-deoxyuridin-5′-yl) tetrahydrogen tetraphosphate
Systematic IUPAC name
O1,O7-Bis{[(2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxyoxolan-2-yl]methyl} tetrahydrogen tetraphosphate
Other names
P1,P4-Bis(5'-uridyl) tetraphosphate; INS-365; Diquafosol tetrasodium
Identifiers
CAS Number
  • 59985-21-6 checkY
  • 211427-08-6 (tetrasodium salt) checkY
3D model (JSmol)
  • Interactive image
ChEMBL
  • ChEMBL1767408
  • ChEMBL221326
ChemSpider
  • 130647
  • 130646 (tetrasodium salt)
IUPHAR/BPS
  • 1736
PubChem CID
  • 148197
  • 148196 (tetrasodium salt)
UNII
  • 7828VC80FJ checkY
  • X8T9SBH9LL (tetrasodium salt) checkY
CompTox Dashboard (EPA)
  • DTXSID40208689 Edit this at Wikidata
InChI
  • InChI=1S/C18H26N4O23P4/c23-9-1-3-21(17(29)19-9)15-13(27)11(25)7(41-15)5-39-46(31,32)43-48(35,36)45-49(37,38)44-47(33,34)40-6-8-12(26)14(28)16(42-8)22-4-2-10(24)20-18(22)30/h1-4,7-8,11-16,25-28H,5-6H2,(H,31,32)(H,33,34)(H,35,36)(H,37,38)(H,19,23,29)(H,20,24,30)/t7-,8-,11-,12-,13-,14-,15-,16-/m1/s1
    Key: NMLMACJWHPHKGR-NCOIDOBVSA-N
  • InChI=1/C18H26N4O23P4/c23-9-1-3-21(17(29)19-9)15-13(27)11(25)7(41-15)5-39-46(31,32)43-48(35,36)45-49(37,38)44-47(33,34)40-6-8-12(26)14(28)16(42-8)22-4-2-10(24)20-18(22)30/h1-4,7-8,11-16,25-28H,5-6H2,(H,31,32)(H,33,34)(H,35,36)(H,37,38)(H,19,23,29)(H,20,24,30)/t7-,8-,11-,12-,13-,14-,15-,16-/m1/s1
    Key: NMLMACJWHPHKGR-NCOIDOBVBD
  • O=C1\C=C/N(C(=O)N1)[C@@H]2O[C@@H]([C@@H](O)[C@H]2O)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]4O[C@@H](N\3C(=O)NC(=O)/C=C/3)[C@H](O)[C@@H]4O
Properties
Chemical formula
 C18H26N4O23P4
Molar mass 790.306 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references
Chemical compound

Diquafosol (tradename Diquas) is a pharmaceutical drug for the treatment of dry eye disease. It was approved for use in Japan in 2010.[1] It is formulated as a 3% ophthalmic solution of the tetrasodium salt.

Its mechanism of action involves agonism of the P2Y2 purinogenic receptor.[2]

References

  1. ^ "Santen and Inspire Announce Approval of DIQUAS for Dry Eye Treatment in Japan". April 16, 2010.
  2. ^ Pendergast, W; Yerxa, BR; Douglass Jg, 3rd; Shaver, SR; Dougherty, RW; Redick, CC; Sims, IF; Rideout, JL (2001). "Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5'-polyphosphates". Bioorganic & Medicinal Chemistry Letters. 11 (2): 157–60. doi:10.1016/S0960-894X(00)00612-0. PMID 11206448.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  • v
  • t
  • e
Receptor
(ligands)
P0 (adenine)
P1
(adenosine)
P2
(nucleotide)
P2X
(ATPTooltip Adenosine triphosphate)
P2Y
Transporter
(blockers)
CNTsTooltip Concentrative nucleoside transporters
ENTsTooltip Equilibrative nucleoside transporters
PMATTooltip Plasma membrane monoamine transporter
Enzyme
(inhibitors)
XOTooltip Xanthine oxidase
Others
Others
See also: Receptor/signaling modulators